ARTIVION, INC. (AORT) Q3 2025 10-Q Quarterly Report
Filed: Nov 7, 2025Period ending Sep 30, 2025
Health Care
Surgical & Medical Instruments & ApparatusSEC EDGAR ARTIVION, INC. (AORT) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 7, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
ARTIVION, INC. Q3 2025 10-Q Analysis
Management Discussion & Analysis
- • Capital expenditures $11.5M for nine months ended Sep 30, 2025 vs $9.8M YoY
- • Capex focused on manufacturing equipment, software, computer equipment, and leasehold improvements
Risk Factors
- • New risk: Italian medical device payback reduced by 75% after judicial challenges, finalized 2025 payment ~€0.1M reflecting regulatory/tax risk update
- • Updated regulatory risk: FDA Mtb tissue processing guidance withdrawn May 2025, public comments filed, potential to reduce available safe implantable tissue supply
ARTIVION, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$113M
▲ +18.4% YoY▲ +0.4% QoQ
Net Income
$7M
▲ +384.2% YoY▲ +383.4% QoQ
Gross Margin
65.6%
▲ +191bp YoY▲ +89bp QoQ
Operating Margin
11.1%
▲ +648bp YoY▲ +363bp QoQ
Net Margin
5.7%
▲ +812bp YoY▲ +454bp QoQ
ROE
1.5%
Total Assets
$858M
EPS (Diluted)
$0.14
▲ +333.3% YoY▲ +366.7% QoQ
Operating Cash Flow
$22M
▲ +94.3% YoY▲ +48.3% QoQ
Source: XBRL data from ARTIVION, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ARTIVION, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.